Fewer than 20% of addiction treatment facilities provide on-site wound care for xylazine injuries, despite 275% rise in xylazine-related overdose deaths

Only 19.5% of addiction treatment facilities provide on-site wound care services, even though 43.6% of addiction professionals have treated patients with xylazine-associated wounds. Xylazine, an animal tranquilizer increasingly found mixed with fentanyl, causes severe necrotic skin wounds that require specialized wound care unrelated to traditional addiction treatment. Why it matters: patients with xylazine wounds who enter addiction treatment cannot get their wounds treated at the same facility, so they must navigate separate wound care appointments at hospitals or clinics that may stigmatize people who use drugs, so many patients avoid wound care entirely and more than half self-medicate wound pain with heroin or fentanyl, so untreated wounds progress to tissue necrosis requiring amputation, so the addiction treatment system fails to address the most visible and medically urgent complication of the current drug supply while xylazine-related overdose deaths rose 275% between 2019 and 2022. The structural root cause is that addiction treatment programs were designed around a behavioral health model focused on counseling and medication management, not acute medical care, and the rapid emergence of xylazine in the illicit drug supply (virtually 100% of tested samples in Philadelphia by 2024) outpaced the addiction treatment workforce's capacity to retrain, with only 26.9% of physicians in addiction settings having any wound care training or certification.